BioCentury
ARTICLE | Clinical News

ABT-493: Additional Phase IIb data

April 25, 2016 7:00 AM UTC

Data from 54 treatment-naive or pegylated interferon treatment-experienced, non-cirrhotic patients with HCV genotype 2 infection in the open-label, international Phase IIb SURVEYOR-II trial showed that once-daily oral 300 mg ABT-493 plus 120 mg ABT-530 for 8 weeks led to an SVR 12 weeks after the end of treatment in 98% of patients. In 29 treatment-naive, non-cirrhotic patients with HCV genotype 3 infection, once-daily 300 mg ABT-493 plus 120 mg ABT-530 for 8 weeks led to an SVR12 rate of 97%. In 48 treatment-naive, cirrhotic patients with HCV genotype 3 infection, once-daily 300 mg ABT-493 plus 120 mg ABT-530 for 12 weeks with or without ribavirin led to an SVR12 rate of 100%. Data were presented at the European Association for the Study of the Liver meeting in Barcelona. AbbVie has previously reported data from the trial (see BioCentury, Nov. 23, 2015). ...